UKPDS overview
-
Upload
peninsulaendocrine -
Category
Health & Medicine
-
view
2.262 -
download
5
Transcript of UKPDS overview
![Page 1: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/1.jpg)
ukpds
The UKThe UKProspectiveProspective
DiabetesDiabetesStudyStudy
![Page 2: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/2.jpg)
ukpds
• 20-year multicenter RCT -Interventional Trial from 1977 to 1997
• Intensive diabetes control and reduction in complications
5,102 patients with newly-diagnosed type 2 diabetes recruited between 1977 and 1991
FPG between 6.1 to 15 mmol
Randomized to conventional therapy vs. intensive therapy
Median follow-up 10.0 years, range 6 to 20 years
![Page 3: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/3.jpg)
ukpds
Glucose Interventional TrialGlucose Interventional Trial
Intensive
Conventional
Intensive
2,729 Intensive
with sulfonylurea(glibenclamide or
chlorpropramide)/insulin
1,138 (411 overweight) Conventional
with diet
342 (all overweight) Intensive
with metformin
P
Trial end1997
P
5,102Newly-diagnosed
type 2 diabetes
744Diet failure
FPG >15 mmol/l
149Diet satisfactory FPG <6 mmol/l
DietaryRun-in
4209
Randomisation1977-1991
Mean age 54 years(IQR 48–60)
![Page 4: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/4.jpg)
ukpds
• Aim• Conventional group- best achievable FPG• Intensive group FPG <6mmol
![Page 5: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/5.jpg)
ukpds
Any Diabetes Related EndpointAny Diabetes Related Endpoint
First occurrence of any one of:
• diabetes related death
• non fatal myocardial infarction, heart failure or angina
• non fatal stroke
• amputation
• renal failure
• retinal photocoagulation or vitreous haemorrhage
• cataract extraction or blind in one eye
![Page 6: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/6.jpg)
ukpds
Diabetes Related DeathsDiabetes Related Deaths
Any of:
• fatal myocardial infarction or sudden death
• fatal stroke
• death from peripheral vascular disease
• death from renal disease
• death from hyper/hypoglycaemia
![Page 7: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/7.jpg)
ukpds
HbAHbA1c1c (7 vs 7.9%) (7 vs 7.9%)cross-sectional, median values
06
7
8
9
0 3 6 9 12 15
HbA 1
c (%
)
Years from randomisation
Conventional
Intensive
6.2% upper limit of normal range
![Page 8: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/8.jpg)
ukpds
Aggregate Clinical EndpointsAggregate Clinical Endpoints
Favoursconventional
0.5 1 2
0.88
0.90
0.94
0.84
1.11
0.75
0.029
0.34
0.44
0.052
0.52
0.0099
Any diabetes related endpoint
Diabetes related deaths
All cause mortality
Myocardial infarction
Stroke
Microvascular
RR p
Favoursintensive
Relative Risk& 95% CI
![Page 9: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/9.jpg)
ukpds
Microvascular Endpoints (cumulative)Microvascular Endpoints (cumulative)
p=0.0099
0%
10%
20%
30%
0 3 6 9 12 15
% o
f pa
tient
s w
ith a
n ev
ent
Years from randomisation
Intensive
Conventional
Risk reduction 25%(95% CI: 7% to 40%)
renal failure or death, vitreous haemorrhage or photocoagulation346 of 3867 patients (9%)
![Page 10: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/10.jpg)
ukpds
MicroalbuminuriaMicroalbuminuriaUrine albumin >50 mg/L
0.89
0.83
0.88
0.76
0.67
0.70
0.24
0.043
0.13
0.00062
0.000054
0.033
Baseline
Three years
Six years
Nine years
Twelve years
Fifteen years
RR p 0.5 1 2
Relative Risk& 99% CI
Favoursconventional
Favoursintensive
<
![Page 11: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/11.jpg)
ukpds
Progression of RetinopathyProgression of RetinopathyTwo step change in Early Treatment Diabetic Retinopathy Study (ETDRS) scale
1.03
0.83
0.83
0.79
0.78
0.017
0.012
0.015
0 - 3 years
0 - 6 years
0 - 9 years
0 - 12 years
RR p 0.5 1 2
Relative Risk& 99% CI
Favoursconventional
Favoursintensive
![Page 12: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/12.jpg)
ukpds
Glucose Control Study SummaryGlucose Control Study Summary
The intensive glucose control policy maintained a lower HbA1c by mean 0.9 % over a median follow up of 10 years from diagnosis of type 2 diabetes with reduction in risk of:
12% for any diabetes related endpoint p=0.02925% for microvascular endpoints p=0.0099
16% for myocardial infarction p=0.05224% for cataract extraction p=0.046
21% for retinopathy at twelve years p=0.01533% for albuminuria at twelve yearsp=0.000054
![Page 13: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/13.jpg)
ukpds
• Major hypoglycemic episode• Conventional 0.7% • Intensive Chlorpropramide 1%, glibenclamide 1.4%, insulin 1.8%
• Wt Gain • insulin 4 kg, glibenclamide 1.7kg chlorpropramide 2.6 kg
![Page 14: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/14.jpg)
ukpds
Sulphonylurea or insulinSulphonylurea or insulin
Sulphonylurea therapy• no evidence of deleterious effect on myocardial
infarction, sudden death or diabetes related deaths
Insulin therapy• no evidence for more atheroma-related disease
![Page 15: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/15.jpg)
ukpds
UKPDS SummaryUKPDS Summary• There is a direct relationship between the risk of
complications of diabetes and glycaemia over time
• The lower the glycaemia the lower the risk for complications
• The rate of increase of risk for microvascular disease with hyperglycaemia is greater than that for macro vascular disease
![Page 16: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/16.jpg)
ukpds
ConclusionConclusion
The UKPDS has shown that intensive blood
glucose control reduces the risk of diabetic
complications, the greatest effect being on
microvascular complications
![Page 17: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/17.jpg)
ukpds
Sulphonylurea or Insulin : Summary 1Sulphonylurea or Insulin : Summary 1
• all three therapies were similarly effective in reducing HbA1c
• all three therapies had equivalent risk reductionfor major clinical outcomes compared with conventional policy
• in those allocated to chlorpropamide there was equivalent reduction of risk of microalbuminuria but no reduction of risk of progression of retinopathy
![Page 18: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/18.jpg)
ukpds
Does metformin in Does metformin in overweight diabetic patients overweight diabetic patients
have any advantages or have any advantages or disadvantages?disadvantages?
UK Prospective Diabetes StudyUK Prospective Diabetes Study
![Page 19: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/19.jpg)
ukpds
0.0
0.1
0.2
0.3
0.4
0 3 6 9 12 15
Pro
port
ion
of p
atie
nts
with
eve
nts
Years from randomisation
Conventional (411)
Intensive (951)
Metformin (342)
Diabetes related deathsDiabetes related deaths
M v Ip=0.11
overweight patients
M v C p=0.017
![Page 20: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/20.jpg)
ukpds
Myocardial InfarctionMyocardial Infarction
M v Ip=0.12
overweight patients
0.0
0.1
0.2
0.3
0.4
0 3 6 9 12 15
Pro
port
ion
of p
atie
nts
with
eve
nts
Years from randomisation
Conventional (411)
Intensive (951)
Metformin (342)
M v Cp=0.010
![Page 21: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/21.jpg)
ukpds
0.0
0.1
0.2
0.3
0 3 6 9 12 15
Pro
port
ion
of p
atie
nts
with
eve
nts
Years from randomisation
Conventional (411)
Intensive (951)
Metformin (342)
Microvascular endpointsMicrovascular endpoints
M v Ip=0.39
overweight patients
M v Cp=0.19
![Page 22: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/22.jpg)
ukpds
Metformin ComparisonsMetformin Comparisons
favours metformin
favours conventional
overweight patientsRR p
Any dia b e t es re l ate d e n dpo i n tM e t for min 0 . 68 0 . 002 3
Diab e t es re l ate d d e a thsM e t for min 0 . 58 0 . 017
All ca use m ort ali tyM e t for min 0 . 64 0 . 011
Myo c ardia l in f arc tio nM e t for min 0 . 61 0 . 01
RR (95% CI)
0.2 1 5
![Page 23: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/23.jpg)
ukpds
Metformin ComparisonsMetformin Comparisons
favours metformin or
intensive
favours conventional
overweight patientsM v I n t RR p
Any dia b e t es re l ate d e n dpo i n tM e t for minI n t ensiv e
p=0 . 0 0 3 40 . 680 . 93
0 . 002 30 . 46
Diab e t es re l ate d d e a thsM e t for minI n t ensiv e
p=0 . 1 10 . 580 . 80
0 . 0170 . 19
All ca use m ort ali tyM e t for minI n t ensiv e
p=0 . 0 2 10 . 640 . 92
0 . 0110 . 49
Myo c ardia l in f arc tio nM e t for minI n t ensiv e
p=0 . 1 20 . 610 . 79
0 . 010 . 11
RR (95% CI)
0.2 1 5
![Page 24: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/24.jpg)
ukpds
Sulphonylurea plus MetforminSulphonylurea plus Metformin
• patients primarily randomised to intensive therapy with sulphonylurea were not given additional metformin until their fpg was >15 mmol/L or they developed hyperglycaemic symptoms
• in view of the progressive hyperglycaemia in these patients, a protocol modification was made to secondarily randomise the subset of patients who were on maximum sulphonylurea therapy and had fpg >6 mmol/L to earlier addition of metformin
![Page 25: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/25.jpg)
ukpds
AimAim
• the aim of this secondary randomisation was to assess the degree to which glycaemic control might be improved by early combination therapy with metformin
• in view of the interesting results in the primary metformin study a secondary analysis was undertaken to examine any endpoints that had occurred
![Page 26: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/26.jpg)
ukpds
Aggregate EndpointsAggregate Endpoints
1.04
1.96
1.60
1.09
1.21
0.84
0.78
0.039
0.041
0.73
0.61
0.62
Any diabetes related endpoint
Diabetes related deaths
All cause mortality
Myocardial infarction
Stroke
Microvascular
RR pMedian follow up 6.6 years 0.1 1 10
Favourssulphonylureaalone
Favoursadded
metformin
Relative Risk& 95% CI
*
* interpret with caution in view of small numbers : 26 deaths on sulphonylurea plus metformin versus 14 deaths on sulphonylurea alone
![Page 27: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/27.jpg)
ukpds
Metformin in Overweight PatientsMetformin in Overweight Patients
• compared with conventional policy
32% risk reduction in any diabetes-related endpoints p=0.002342% risk reduction in diabetes-related deaths p=0.01736% risk reduction in all cause mortalityp=0.01139% risk reduction in myocardial infarction p=0.01
![Page 28: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/28.jpg)
ukpds
Metformin : SummaryMetformin : Summary
• the addition of metformin in patients already treated with sulphonylurea requires further study
• on balance, metformin treatment would appear to be advantageous as primary pharmacological therapy in diet-treated overweight patients
![Page 29: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/29.jpg)
ukpds
Blood Pressure Blood Pressure Control StudyControl Study
UK Prospective Diabetes StudyUK Prospective Diabetes Study
![Page 30: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/30.jpg)
ukpds
Blood Pressure Control Study : AimsBlood Pressure Control Study : Aims
to determine whether
• tight blood pressure control policy can reduce morbidity and mortality in Type 2 diabetic patients
• ACE inhibitor (captopril) or Beta blocker (atenolol) is advantageous in reducing the risk of development of clinical complications
![Page 31: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/31.jpg)
ukpds
Inclusion criteriaInclusion criteria
patients NOT on anti-hypertensive therapy
systolic >160 and/or diastolic > 90 mmHg
patients already ON anti-hypertensive therapy
systolic >150 and/or diastolic > 85 mmHg
excluded if:
required strict blood pressure control; severe illness;
contraindication to study medication or declined
informed consent
![Page 32: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/32.jpg)
ukpds
Patient CharacteristicsPatient Characteristics
1148 Type 2 diabetic patients
age 56 years
gender male / female 55% / 45%
ethnic groups Caucasian 87%
Asian 6%
Afro-caribbean 7%
Body Mass Index 29 kg/m2
HbA1c 6.8 %
systolic / diastolic blood pressure 160 / 94 mmHg
urine albumin > 50 mg/l 18%
![Page 33: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/33.jpg)
ukpds
RandomisationRandomisation
on antihypertensive therapyn = 421
not on antihypertensive therapyn = 727
avoid ACE inhibitor : Beta blockern = 390
34%
less tight blood pressure controlaim : BP < 180/105 mmHg
ACE inhibitorn = 400
35%
Beta blockern = 358
31%
tight blood pressure controlaim : BP < 150 / 85 mmHg
randomisation
1148 hypertensive patients
![Page 34: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/34.jpg)
ukpds
Blood Pressure : Tight vs Less Tight Control Blood Pressure : Tight vs Less Tight Control
60
80
100
140
160
180
0 2 4 6 8
mm
Hg
Years from randomisation
cohort, median values
Less tight control Tight control
![Page 35: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/35.jpg)
ukpds
mmHg baseline mean over 9 years
Less tight control 160 / 94 154 / 87
Tight control 161 / 94 144 / 82
difference 1 / 0 10 / 5
p n.s. <0.0001
ACE inhibitor 159 / 94 144 / 83
Beta blocker 159 / 93 143 / 81
difference 0 / 0 1 / 1
p n.s. n.s. / p=0.02
Mean Blood PressureMean Blood Pressure
![Page 36: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/36.jpg)
ukpds
Therapy requirementTherapy requirement
1 2 3 4 5 6 7 80
20
40
60
80
100
% o
f pa
tient
s
LessTight Control Policy
1 2 3 4 5 6 7 8
Years from randomisation
None one two > two
Tight Control Policy
number of antihypertensive agents
![Page 37: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/37.jpg)
ukpds
Any diabetes-related endpointsAny diabetes-related endpoints
0%
10%
20%
30%
40%
50%
0 3 6 9
% o
f pa
tient
s w
ith e
vent
s
Years from randomisation
Tight blood pressure control (758)
Less tight blood pressure control (390)
risk reduction24% p=0.0046
![Page 38: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/38.jpg)
ukpds
Diabetes-related deathsDiabetes-related deaths
0%
5%
10%
15%
20%
0 3 6 9
% o
f pa
tient
s w
ith e
vent
s
Years from randomisation
Tight blood pressure control (758)
Less tight blood pressure control (390)
risk reduction32% p=0.019
![Page 39: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/39.jpg)
ukpds
Myocardial InfarctionMyocardial Infarction
0%
5%
10%
15%
20%
25%
0 3 6 9
% o
f pa
tient
s w
ith e
vent
Years from randomisation
Tight Blood Pressure Control (758)
Less Tight Blood Pressure Control (390)
risk reduction21% p=0.13
![Page 40: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/40.jpg)
ukpds
StrokeStroke
0%
5%
10%
15%
20%
25%
0 3 6 9
% p
atie
nts
with
eve
nt
Years from randomisation
Tight Blood Pressure Control (758)
Less Tight Blood Pressure Control (390)
risk reduction44% p=0.013
![Page 41: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/41.jpg)
ukpds
Microvascular endpointsMicrovascular endpoints
0%
5%
10%
15%
20%
25%
0 3 6 9
% p
atie
nts
with
eve
nt
Years from randomisation
Tight Blood Pressure Control (758)
Less Tight Blood Pressure Control (390)
risk reduction37% p=0.0092
![Page 42: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/42.jpg)
ukpds
Heart FailureHeart Failure
0%
5%
10%
15%
20%
25%
0 3 6 9
% p
atie
nts
with
eve
nt
Years from randomisation
Tight Blood Pressure Control (758)
Less Tight Blood Pressure Control (390)
risk reduction 56% p=0.0043
![Page 43: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/43.jpg)
ukpds
Progression of Retinopathy : 2 step changeProgression of Retinopathy : 2 step change
Years from randomisationnumbers above bars are % affected
243 461 207 411 152 3000
20
40
60
% p
atie
nts
23 20
37
28
51
34
3 years 6 years 9 years
p=0.38 p=0.019 p=0.004
![Page 44: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/44.jpg)
ukpds
Deterioration of Vision : 3 lines on ETDRS chartDeterioration of Vision : 3 lines on ETDRS chart
Years from randomisationnumbers above bars are % affected
% p
atie
nts
293 575 257 523 180 3320
10
20
30
7 59
8
19
10
3 years 6 years 9 years
p=0.40 p=0.47 p=0.004
![Page 45: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/45.jpg)
ukpds
Urine Albumin >50 mg/LUrine Albumin >50 mg/L
Years from randomisationnumbers above bars are % affected
% p
atie
nts
317 618 274 543 166 2990
10
20
30
40
24
18
29
20
33
29
3 years 6 years 9 years
p=0.008p=0.052 p=0.33
![Page 46: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/46.jpg)
ukpds
in 1148 Type 2 diabetic patients a tight blood pressure control policy which achieved blood pressure of 144 / 82 mmHg gave reduced risk for
any diabetes-related endpoint 24% p=0.0046
diabetes-related deaths 32% p=0.019
stroke 44% p=0.013
microvascular disease 37% p=0.0092
heart failure 56% p=0.0043
retinopathy progression 34% p=0.0038
deterioration of vision 47% p=0.0036
Blood Pressure Control StudyBlood Pressure Control Study
![Page 47: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/47.jpg)
ukpds
Do ACE inhibitors or Do ACE inhibitors or Beta Blockers Beta Blockers
have any specific advantages have any specific advantages or disadvantages?or disadvantages?
UK Prospective Diabetes StudyUK Prospective Diabetes Study
![Page 48: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/48.jpg)
ukpds
Blood Pressure : ACE inhibitor vs Beta blockerBlood Pressure : ACE inhibitor vs Beta blocker
60
80
100
140
160
180
0 2 4 6 8
mm
Hg
Years from randomisation
cohort, median values
Less tight control ACE inhibitor Beta blocker
![Page 49: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/49.jpg)
ukpds
Reasons for non-complianceReasons for non-complianceCaptopri l(n=400 )
Atenolo l(n=358 ) p
non- compl iant 88 (22%) 125 (35%) <0.0001
cough 16 (4%) 0 <0.0001
inc rea sed creatini ne 5 (1%) 0 0.064
c laudi cation,col d finger s or toes
0 15 (4%) <0.0001
bron cho spas m 0 22 (6%) <0.0001
impotenc e 1 (0%) 6 (2%) 0.057
![Page 50: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/50.jpg)
ukpds
Any Diabetes Related Endpoint (cumulative)Any Diabetes Related Endpoint (cumulative)429 of 1148 patients (37%)
0%
10%
20%
30%
40%
50%
0 3 6 9
% o
f pa
tient
s w
ith a
n ev
ent
Years from randomisation
ACE inhibitor (n=400)
Beta blocker (n=358)
Less tight BP control (n=390)
ACE vs Beta blocker p=0.43
Less tight vs Tightp=0.0046
![Page 51: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/51.jpg)
ukpds
Diabetes Related Deaths (cumulative)Diabetes Related Deaths (cumulative)144 of 1148 patients (13%)
0%
5%
10%
15%
20%
0 3 6 9
% o
f pa
tient
s w
ith a
n ev
ent
Years from randomisation
ACE inhibitor (n=400)
Beta blocker (n=358)
Less tight BP control (n=390)
ACE vs Beta blocker p=0.28
Less tight vs Tightp=0.019
![Page 52: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/52.jpg)
ukpds
Microvascular Endpoints (cumulative)Microvascular Endpoints (cumulative)renal failure or death, vitreous haemorrhage or photocoagulation
122 of 1148 patients (11%)
0%
5%
10%
15%
20%
0 3 6 9
% o
f pa
tient
s w
ith a
n ev
ent
Years from randomisation
ACE inhibitor
Beta blocker
Less tight BP control
ACE vs Beta blocker p=0.30
Less tight vs Tightp=0.0092
![Page 53: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/53.jpg)
ukpds
Aggregate Clinical EndpointsAggregate Clinical Endpoints
1.10
1.27
1.14
1.20
1.12
1.29
0.43
0.28
0.44
0.35
0.74
0.30
Any diabetes related endpoint
Diabetes related deaths
All cause mortality
Myocardial infarction
Stroke
Microvascular
RR p 0.5 1 2
Relative Risk& 95% CI
>
>
FavoursBeta blocker
FavoursACE inhibitor
![Page 54: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/54.jpg)
ukpds
Surrogate endpointsSurrogate endpoints
RR p
Reti nopathy 2 step progress ionmedian 1.5 years 0.99 0.75median 4.5 years 0.99 0.82median 7.5 years 0.91 0.28
Ur ine albumi n > 50 mg/L3 year s 1.11 0.556 year s 0.93 0.659 year s 1.20 0.31
Ur ine albumi n > 300 mg/L3 year s 1.41 0.446 year s 0.75 0.439 year s 0.48 0.090
Relative Risk & 99% CI
favours ACE inhibitor
favours Beta blocker
0.1 1 10
![Page 55: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/55.jpg)
ukpds
ConclusionConclusion
ACE inhibitors and Beta blockers were equally effective in lowering mean blood pressure in hypertensive patients with type 2 diabetes and in reducing the risk of:
• any diabetes related endpoint• diabetes related deaths• microvascular endpoints
![Page 56: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/56.jpg)
ukpds
Potential implications Potential implications for clinical care of for clinical care of diabetic patientsdiabetic patients
UK Prospective Diabetes StudyUK Prospective Diabetes Study
![Page 57: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/57.jpg)
ukpds
UK Prospective Diabetes StudyUK Prospective Diabetes Study
An intensive glucose control policy HbA1c 7.0 % vs 7.9 %
reduces risk of
any diabetes-related endpoints 12% p=0.030 microvascular endpoints 25% p=0.010 myocardial infarction 16% p=0.052
A tight blood pressure control policy 144 / 82 vs 154 / 87 mmHg
reduces risk of
any diabetes-related endpoint 24% p=0.005 microvascular endpoint 37% p=0.009 stroke 44% p=0.013
![Page 58: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/58.jpg)
ukpds
Choice of TherapiesChoice of Therapies
diabetes :• each of the available therapies studied can be used • in overweight, diet-treated patients, metformin may
be advantageous
hypertension :• Beta blockers and ACE inhibitors each provide
protection
![Page 59: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/59.jpg)
ukpds
Which goals of therapy?Which goals of therapy?
• current guidelines suggest HbA1c <7%
• the risk of diabetic complications was reduced in the UKPDS trial which achieved a median HbA1c 7.0%in the intensive glucose control group
• this HbA1c level is in accord with current guidelinesbut is difficult to accomplish in some patients
• epidemiological analysis suggests that any reduction of hyperglycaemia would be advantageous
![Page 60: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/60.jpg)
ukpds
Which goals of therapy?Which goals of therapy?
• current guidelines suggest blood pressure<140 / 85 mmHg or <130 / 85 mmHg
• the risk of diabetic complications was reducedin the UKPDS blood pressure control trialwhich achieved a mean blood pressure 144 / 82 mmHg in the tight control group
• this result is in accord with current guidelines,which are also supported by the epidemiological analysis
![Page 61: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/61.jpg)
ukpds
UK Prospective Diabetes StudyUK Prospective Diabetes Study
The UKPDS has shown conclusively that :
• intensive therapy to reduce glycaemia is worthwhile as it reduces risk of complications
• tight blood pressure control is worthwhile as it reduces risk of complications
• there are no major differences between the therapies tested
• reduction in risk of complications of diabetes is a realisable goal
![Page 62: UKPDS overview](https://reader036.fdocuments.us/reader036/viewer/2022062303/556cb957d8b42ab70c8b504c/html5/thumbnails/62.jpg)
ukpds
Beneficial Effects of Intensive TherapyBeneficial Effects of Intensive Therapy
The UKPDS has shown that
more intensive monitoring
more intensive use of existing therapies
which improves
blood glucose control
blood pressure control
can reduce the risk of diabetic complications